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Abstract: Combined fluorodeoxyglucose-positron emission tomog-
raphy (PET)/ computed tomography (CT) imaging has the potential
to become the new standard imaging modality for the staging and
restaging of patients with lung cancer. PET/CT is superior to PET
alone, CT alone, and visual correlation of both techniques sepa-
rately. In particular, it improves T3 and T4 staging and delineation
of tumors associated with atelectasis. CT contrast media enhance-
ment is probably only still needed when a substantial mediastinal
tumor component is present and delineation of tumor from vascular
structures is relevant. PET/CT is very accurate in detecting medias-
tinal nodal disease, but false-positive results are sufficiently frequent
to require sampling in some positive cases. Whole-body PET/CT is
the most sensitive technique for detecting extracranial metastatic
disease, unexpected additional primary malignancies, and recur-
rence. Innovations include therapy monitoring, prognostic informa-
tion, evaluation of small-cell lung cancer, its use for radiotherapy
planning, and four-dimensional respiratory gating acquisition.
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All relevant imaging modalities, including computed to-mography (CT), magnetic resonance imaging (MRI), and
positron emission tomography (PET), are used for imaging
lung cancer. A multidisciplinary approach contributes to a
correct staging and restaging, and therapy becomes more
successful. In lung cancer, both CT and PET using fluorode-
oxyglucose (FDG) play an important role in the diagnosis and
staging of patients with lung cancer. CT provides excellent
morphologic information but has significant limitations in
differentiating between benign and malignant lesions either in
an organ or in lymph nodes. As the previous revision has
brilliantly explained, PET using FDG provides excellent
metabolic information of the tumoral lesions in a whole-body
study and improves the rate of detection of mediastinal lymph
node metastases as well as extrathoracic metastases when
compared with CT. Limitations of PET are that the technique
provides little information on the exact anatomic localization
of lesions and that FDG is not specific for malignant tissue.
Fusing the morphologic and functional datasets may provide
further diagnostic confidence. Faulty co-registration as a
result of motion-induced misalignment in the abdomen and
chest has, so far, limited all software-based image fusion
tools. This limitation can be overcome by an integrated
PET/CT system that provides co-registered morphologic and
functional datasets as part of a single examination.
The first prototype of a PET/CT scanner was developed
at the University of Pittsburg in 1998, and a combined
PET/CT system became commercially available in the United
States in the spring of 2001.1 In Europe, the first clinical
PET/CT was set up in the University Hospital of Zurich in
2001. Our institution in Barcelona, Spain, started in 2003;
since then, more than 1500 scans have been performed in
patients with suspected or diagnosed lung cancer. Within 3
years, more than 450 PET/CT scanners had been sold world-
wide, with the majority being in the United States, and
PET/CT scanners comprise more than 80% of total PET
scanner sales since 2003.2
The PET/CT scanners combine a multidetector helical
CT (located proximally in the gantry) to provide the anatom-
ical information with a dedicated PET ring (located distally in
the gantry) to provide metabolic information. Automatic and
exact fusion of both modalities is performed by a dedicated
workstation. In our institution, all scans are obtained in a
Discovery ST scanner (General Electric Healthcare, Milwa-
kee, WI).
Compared with PET, using integrated PET/CT for
patients with lung cancer presents three important advan-
tages: (1) increases the accuracy and certainty of locating
lesions; (2) reduces time of acquisition (more rapid scans than
PET alone) and final diagnosis (CT and PET in a single
scanning session); and (3) improves staging and restaging
accuracy (differentiating physiological from pathological fo-
ci).3,4 PET/CT results can therefore change the patient’s
management. In overall staging of non–small-cell lung can-
cer, PET/CT provides more information than PET alone, CT
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alone, and probably more than the visual correlation of PET
and CT performed separately.5–10
Current Recommendations
Current recommendations for the use of PET/CT in
lung cancer are obviously the same as for PET, with some
important advantages in certain indications. As previously
reported for FDG-PET in lung cancer, PET/CT is also widely
accepted for imaging lung nodules and staging and restaging
non–small-cell lung cancer.11
Integrated PET/CT imaging from the head to the upper
legs is performed in all remitted patients with proven or
suspected non–small-cell lung cancer, which allows a com-
plete tumor node metastases staging.
The primary tumor can be resectable depending on its
extension (T stage), which is usually assessed by CT. How-
ever, the low accuracy of chest CT in the evaluation of
invasion of the chest wall or involvement of the mediastinum
and the correct differentiation between tumor and peritumoral
atelectasis often limits precise T staging with CT. A disad-
vantage of PET is the limited anatomic resolution, which
makes the assessment of tumor extension unreliable, partic-
ularly if the tumor infiltrates the chest wall or the mediasti-
num. Integrated PET/CT provides important information on
the exact demarcation of the tumor and improves T3 and T4
stage assessment. A fundamental, but easily overlooked,
premise when discussing the use of imaging for T staging is
that the primary tumor can be clearly defined. In fact, it may
be difficult to distinguish the tumor from distal collapsed or
consolidated lung on CT, and this can result in overestimation
of tumor size and extent of parietal pleural contact. It has
been shown that PET/CT is a useful tool for the differentia-
tion between tumor, which is hypermetabolic, and peritu-
moral atelectasis, which is usually normometabolic, although
it also can be invaded by the tumor (pattern of replacement
atelectasis).12 (Figure 1). This may be particularly important
for the planning of radiotherapy, in which the information
provided contributes to a change in the radiation field in
approximately 30 to 40% of patients.13
CT, MRI, and PET (and obviously PET/CT) can clearly
show the presence of extensive tumor within the mediasti-
num, but lesser degrees of invasion cannot be reliably diag-
nosed or excluded by either modality. Although CT is accu-
rate in predicting non-invasion of the chest wall and
mediastinum, it is less accurate in positively diagnosing
invasion of these structures. Glazer et al.14 correlated three
features of the tumor observed in CT with resectability: (1)
less than 3 cm of mediastinal contact, (2) maintained fat plane
of separation form mediastinum, and (3) less than 90 degrees
of circumferential aortic contact. These criteria are useful in
predicting resectability but are unreliable evidence for irre-
sectability: inflammatory changes adjacent to the tumor can
show identical patterns of extensive contact and loss of the fat
plane. Further research is needed to evaluate the potential
additional diagnostic impact of intravascular contrast agents
when performing a PET/CT.15
A peripheral lung tumor may transgress the parietal
pleural and invade the ribs and intercostal muscles. Both CT
and MRI can clearly show these findings of chest wall
invasion. Lesser degrees of invasion, such as limited pleural
thickening, are produced not only in invasion but also in
inflammation-fibrosis and adherences adjacent to the tumor.
PET/CT can provide additional information in these cases.
PET is very effective for staging of mediastinal nodes,
without the limitation of the CT in nodes that are less than 1
cm. PET/CT provides exact localization and classification of
affected lymph nodes. Although PET/CT is the most accurate
technique, false-positive results are sufficiently frequent to
require sampling in some cases.16–18
Although FDG-PET is the most sensitive technique for
detecting extracraneal metastatic disease, PET/CT allows its
exact localization so that further therapies can be suitably
managed. In a number of patients diagnosed with primary
lung cancer, second metachronous tumors are sometimes
discovered with PET/CT, mainly localized in the gastrointes-
tinal tract.11,19–21
For patients with a suspected recurrence of non–small-
cell lung cancer, as the group of Haifa has recently published,
PET/CT provides a better anatomic localization of suspicious
lesions compared with PET interpreted with side-by-side CT
data. This improved diagnostic performance of PET/CT has a
further impact of the clinical management of and treatment
planning for the patients.22
Innovations
The most important innovations in PET/CT in its lung
cancer application include (1) the assessment of response and
prediction of outcome, (2) the evaluation of small-cell lung
FIGURE 1. Representative positron emission tomography/
computed tomography images from two patients with lung
cancer associated with atelectasis in which computed to-
mography cannot delineate the exact localization of the tu-
mor. (A) A 60-year-old man with left lung adenocarcinoma
limited to the perihilar region causing distal normometabolic
atelectasis. Unsuspected left adrenal hypermetabolic lesion is
observed consistent with metastases. (B) A 67-year-old man
with squamous cell carcinoma in the upper lobe of left lung
where tumor has replaced the lobe showing extensive hy-
permetabolism (replacement atelectasis).
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cancer, (3) the radiotherapy planning, and (4) the four-
dimensional respiratory gating PET/CT acquisition.23
PET/CT is increasingly used to monitor tumor response
in patients undergoing chemotherapy and chemoradiotherapy
for two reasons. First, because it can assess changes in all the
characteristics of tumor lesions, such as the localization, the
size, the number of lesions, and the metabolic activity, in a
single examination. Second, there is a correlation between
FDG uptake and the prediction of tumor response and patient
outcome very early in the course of therapy. Treatment may
be adjusted according to the chemosensitivity and radiosen-
sitivity of the tumor tissue in an individual patient. Thus,
FDG-PET has an enormous potential to reduce the side
effects and costs of ineffective therapy. (Figure 2).24
It seems likely that PET/CT will play an increasing role
in the management of patients with small-cell lung cancer; in
staging, radiation therapy planning in limited stage disease,
and the assessment of treatment response. Overall, in various
studies, PET upgraded limited disease to extensive disease in
8% to 11% and changed treatment planning for patients with
presumed limited-stage disease.25–28 Patients with negative
scans after therapy had better long-term survival compared
with those who had PET-positive results.29 (Figure 3).
Integrated PET/CT for radiotherapy planning improves
the standardization of volume delineation compared with that
of CT alone and may reduce the risk for geographic misses,
minimizing the dose radiation applied to non-target organs
and changing gross tumor volume and, indeed, planning
tumor volume.30–32
Respiratory motion may reduce the sensitivity of PET
in detecting the pulmonary nodules, especially near the dia-
phragm, as motion artifacts are more frequently encountered.
Respiratory motion also involves tumor motion during the
respiratory cycle, which affects not only quantification of
the tumor but also definition of the planning target volume in
the radiotherapy planning. Four-dimensional respiratory gat-
ing consists of acquiring the same volume throughout the
respiratory cycle. An infrared camera records the patient’s
natural breathing pattern by tracking the movement of chest
sensors during inhalation and exhalation and triggering the
acquisition. For lung tumors, the four-dimension respiratory
gating allows a better accuracy for tumor delineation as it
reduces the partial volume effects. Furthermore, as Nehmeh
et al.33 pointed out, it allows a better quantification of the
radiotracer uptake within the lesions as reflected by the more
consistent and reliable standardized uptake value measure-
ments. It also improves the detection of pulmonary nodules
enhancing its visualization. Four-dimensional respiratory gat-
ing also allows an investigator to follow tumor motion during
the respiratory cycle. This improves definition of the planning
target volume as the location in time of the tumor will be
more accurately known. Moreover, the side effects of radio-
therapy for the neighboring organs at risk will be reduced.
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FIGURE 2. This is a baseline positron emission tomogra-
phy/computed tomography scan of a 51 year-old woman
diagnosed with non–small-cell lung cancer showing a mass
in the right lung, lymph nodes adenopathies, and multiple
pulmonary and bone metastases. After only 1 month of
treatment with gefitinib, the positron emission tomography/
computed tomography scan revealed an important meta-
bolic response.
FIGURE 3. A 42-year-old woman with small-cell lung can-
cer referred for primary staging. Positron emission tomogra-
phy/computed tomography imaging shows extensive dis-
ease involving the left lung, mediastinum, and bone, as
shown in the left sacrum and the right femur. She received
chemotherapy for 5 months, and restaging with a PET/CT 1
month after the completion of treatment showed a com-
plete remission.
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